Crestor vs Repatha
Side-by-side cost comparison based on Medicare Part D data
Crestor
Rosuvastatin
Manufactured by AstraZeneca
Repatha
Evolocumab
Manufactured by Amgen
Crestor costs 96% less per claim than Repatha ($28.00 vs $757.00). A generic version of Crestor is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Crestor | Repatha |
|---|---|---|
| Avg Cost Per Claim | $28.00 | $757.00 |
| Total Medicare Spending | $698.0M | $2.6B |
| Total Beneficiaries | 3,450,000 | 398,000 |
| Total Claims | 24,680,000 | 3,420,000 |
| Annual Cost/Patient | $202.00 | $6,505.00 |
| Year-over-Year Change | -48.2% | +24.6% |
| Generic Available | Yes | No |
| Patent Expiration | Jul 8, 2016 | Aug 27, 2029 |
| Manufacturer | AstraZeneca | Amgen |
| Condition | High Cholesterol | High Cholesterol |
| Generic Name | Rosuvastatin | Evolocumab |
Crestor vs Repatha: What the Data Shows
Crestor (Rosuvastatin) and Repatha (Evolocumab) are both used to treat high cholesterol. Based on Medicare Part D data, Crestor costs $28.00 per claim, which is 96% less than Repatha at $757.00 per claim.
Medicare spent $698.0M on Crestor and $2.6B on Repatha. In terms of patient reach, Crestor serves more beneficiaries (3,450,000 vs 398,000).
Year-over-year spending changed -48.2% for Crestor and +24.6% for Repatha. Repatha saw significant spending growth, suggesting increased utilization or price increases.
Crestor has a generic available, while Repatha remains brand-only until its patent expires Aug 27, 2029.
Frequently Asked Questions
Crestor is cheaper at $28.00 per claim, compared to $757.00 for Repatha. That makes Crestor about 96% less expensive per claim based on Medicare Part D data.
Yes, both Crestor and Repatha are used to treat high cholesterol. Your doctor can help determine which medication is more appropriate for your specific situation.
Crestor has a generic version (Rosuvastatin) available, which is typically much cheaper. Repatha is currently brand-only, with patent expiring Aug 27, 2029.
Medicare Part D spent $698.0M on Crestor covering 3,450,000 beneficiaries, and $2.6B on Repatha covering 398,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.